What Is Atypia? Causes, Risks, and What Happens Next

Atypia is a pathology term meaning that cells look abnormal under a microscope but are not clearly cancerous. It sits in a gray zone between perfectly healthy tissue and outright malignancy, and its significance varies enormously depending on where in the body it appears, what caused it, and how abnormal the cells actually look. The term was introduced by George Papanicolaou, the inventor of the Pap smear, to flag a very low suspicion of cancer or precancer, and it has since spread into diagnostic reporting across nearly every organ system.¹ That breadth is part of what makes the word so confusing for patients who see it on a lab report.

What Pathologists Actually See

When a pathologist calls something “atypical,” they are describing specific visual features of cells that fall outside the normal range. These include cells that are larger than expected, nuclei that are darker or irregularly shaped, uneven ratios between the nucleus and the rest of the cell, clumped chromatin (the material inside the nucleus that carries genetic information), and cells with two or more nuclei when they should have one.² None of these features alone means cancer. They mean something has pushed the cells off their normal course, and the pathologist’s job is to figure out whether the cause is harmless, worrisome, or somewhere in between.

It helps to think of a spectrum. On one end, cells look completely normal. On the other end, cells are clearly malignant with chaotic growth patterns. Atypia lives somewhere in the middle. Sometimes it sits close to the normal end and just reflects a temporary disturbance like inflammation. Other times it sits closer to the malignant end and represents a genuine precancerous change. The word itself does not tell you where on the spectrum you are. That depends on context, and pathologists use additional terms like “mild,” “moderate,” “severe,” “low-grade,” or “high-grade” to narrow it down.

What Makes Cells Look Atypical

Not all atypia signals a problem with the cells themselves. Some of the most common causes are temporary and completely reversible.

Chronic inflammation is one of the biggest drivers. When tissue stays inflamed for a long time, the body floods the area with signaling molecules and reactive oxygen species. If this persists, those inflammatory factors can nudge cells into faster-than-normal division and even interfere with the genes that normally keep cell growth in check.³ The resulting cellular changes can look alarming under a microscope even when they are driven entirely by the body’s repair response rather than by any cancerous process. This is sometimes called “reactive atypia,” and pathologists encounter it constantly in biopsies from inflamed tissues.

Cancer treatments themselves cause atypia. Radiation therapy kills cells by damaging their DNA, and the surviving cells often show dramatic changes: swollen cytoplasm, enlarged nuclei, and multinucleation. Chemotherapy produces similar-looking alterations, though it tends to affect fewer cells overall.⁴ These drug-induced changes are thought to result from the treatment stalling nuclear division rather than triggering malignant transformation, and the cells involved typically do not have the increased DNA content that true cancer cells show.⁵ Still, distinguishing treatment-related atypia from recurrent or new cancer can challenge even experienced pathologists.

Infections, hormonal shifts, and even mechanical irritation of tissue can also produce atypical-looking cells. The common thread is that anything forcing cells to repair or regenerate faster than usual can temporarily distort their appearance.

Atypia in Breast Tissue

Breast atypia is one of the most common scenarios where the term enters a patient’s life, typically after a mammogram leads to a biopsy. The two main types are atypical ductal hyperplasia (ADH), where cells lining the milk ducts look abnormal, and atypical lobular hyperplasia (ALH), involving the lobules that produce milk. Neither is cancer, but both are considered risk markers.

A large study following women after an ADH diagnosis found that their rate of later developing invasive breast cancer was roughly two and a half times higher than in women without ADH. About 6% of women with ADH were estimated to develop invasive breast cancer within ten years.⁶ That means the vast majority did not develop cancer, but the elevated risk is real enough that doctors take it seriously.

For ALH found on a core needle biopsy, guidelines often recommend a follow-up surgical excision because pathologists sometimes find more concerning tissue nearby that the needle missed. In one study examining this approach, a meaningful proportion of ALH cases were “upstaged” to a more serious diagnosis after the area was more thoroughly sampled. Chemoprevention with medications like tamoxifen was also offered, and among patients who took it, none went on to develop breast cancer during follow-up, while one patient who declined the medication did.⁷

One complication with breast atypia is that pathologists don’t always agree on whether it’s present. A study examining how a group of expert breast pathologists in the UK classified the same set of tissue samples found only fair agreement among them, with a statistical measure of consistency hovering around 0.22 on a scale where 1.0 would mean perfect agreement.⁸ That low level of concordance is not unique to breast pathology, and it underscores a real limitation: when the diagnosis itself is subjective, different pathologists looking at the same slide can reach different conclusions. If your biopsy comes back with atypia and the clinical recommendation feels aggressive or uncertain, seeking a second pathology opinion is a reasonable step.

Thyroid Nodules and the “Indeterminate” Category

Thyroid nodules are extremely common, and most are harmless. When a fine-needle aspiration (FNA) biopsy is performed, the cells are classified using a standardized system. One of the categories is “atypia of undetermined significance” (AUS) or “follicular lesion of undetermined significance” (FLUS), which essentially means the cells look a little off but the pathologist cannot say whether the nodule is benign or malignant based on what they see.

The malignancy risk for this category has been a moving target. It was originally estimated at 5 to 15%, but more recent surgical series have found higher rates, in some reports ranging from roughly 25% to over 50% depending on the institution and how the data were collected.⁹ One study found malignancy confirmed by pathology in about a quarter of patients with AUS who went on to surgery, with nodule size over 4 centimeters roughly tripling the odds of a malignant result.¹⁰ Another institution, tracking 160 patients with AUS over time, found a total malignancy rate of about 23% once surgical and follow-up cytology results were combined.¹¹

In practice, an AUS result on thyroid FNA usually leads to one of three paths: a repeat biopsy in a few months to see if the cells look the same, molecular testing on the sample to check for genetic markers associated with thyroid cancer, or surgery if other clinical features (like a large or growing nodule, suspicious ultrasound appearance, or a concerning molecular result) tip the balance. The point is that an “indeterminate” result is not a cancer diagnosis. It’s a signal that more information is needed.

Cervical Atypia and HPV

For many people, the first encounter with the word atypia comes from a Pap smear result reading “atypical squamous cells of undetermined significance,” usually abbreviated ASC-US. This is one of the most common abnormal Pap results and, on its own, carries a low risk of serious disease. Most ASC-US results are driven by human papillomavirus (HPV) infection, and the majority clear on their own without treatment.

The question is how to efficiently sort the few women who do have a precancerous lesion from the many who don’t. One approach is HPV testing, specifically looking for expression of the viral genes E6 and E7 that are most directly involved in driving cells toward cancer. A meta-analysis found that women who tested positive for HPV E6/E7 mRNA had about three times the risk of having or developing a significant precancerous lesion compared to those who tested negative.¹² A negative HPV test after an ASC-US result is very reassuring and typically means you can return to routine screening on a normal schedule.

Cost-effectiveness analyses from different healthcare systems have compared the main follow-up strategies for ASC-US: immediate colposcopy (a closer look at the cervix with magnification), repeat Pap smears, and HPV triage. The most cost-effective approach can vary by setting, but all three are considered acceptable options depending on local resources and patient preferences.¹³

Atypia in the Uterine Lining

Endometrial hyperplasia, an overgrowth of the tissue lining the uterus, is classified by whether it includes atypia. The distinction matters a great deal. Without atypia, endometrial hyperplasia is generally considered a benign condition caused by prolonged estrogen exposure that is not offset by progesterone.¹⁴ It can often be managed with progestin therapy alone.

When atypia is present, the picture changes substantially. A large review combining data from thousands of patients found that roughly 37% of women diagnosed with atypical endometrial hyperplasia already had concurrent endometrial cancer when hysterectomy specimens were examined, and some studies put that figure as high as 50%.¹⁴ This does not mean the atypia caused cancer; it means the biopsy sampling often underestimates what is happening in the rest of the uterus. In a multicenter validation study, the risk of finding carcinoma jumped dramatically when the tissue showed a specific growth pattern called confluent glands, regardless of whether the atypia was graded as low or high. The confluent-gland pattern was independently associated with a roughly 17-fold higher odds of concurrent cancer compared to low-grade atypia without that pattern.¹⁵

Because of these high co-occurrence rates, hysterectomy is the standard recommendation for women with atypical endometrial hyperplasia who have completed childbearing. For younger women who want to preserve fertility, close surveillance and hormonal therapy may be considered, but the monitoring has to be intensive.

Atypical Moles

On the skin, atypia usually comes up in the context of moles. A “dysplastic nevus” is a mole whose cells show architectural disorder and cytological atypia under the microscope. The World Health Organization simplified the grading of these moles in 2018 into two categories: low-grade dysplasia and high-grade dysplasia.¹⁶ Dysplastic nevi are considered important because they are associated with a higher risk of melanoma, though the relationship is more about shared risk factors than a simple one-mole-becomes-one-melanoma pathway.¹⁷

The practical question for patients is whether a severely atypical mole needs to be cut out with wider margins after the initial biopsy. A multicenter retrospective study tracked patients with severely dysplastic moles for at least five years and found that none experienced recurrence at the excision site or progression to melanoma, as long as the initial removal achieved clear margins.¹⁸ This suggests that routine re-excision after a clean removal may not add benefit, though dermatologists will weigh individual factors like margin width, family history, and the total number of atypical moles a patient has.

Why Atypia Causes So Much Anxiety

Getting a pathology report that says “atypical” can feel like half a cancer diagnosis. The ambiguity is stressful precisely because the word lives in a gray zone: it’s not normal, but it’s not cancer, and sometimes the next step is just more waiting and more testing. For breast atypia in particular, research has examined the psychological toll. A study of women at increased breast cancer risk found that both general anxiety and specific worry about breast cancer dropped significantly after they received clear, personalized communication about what their risk actually meant in concrete terms.¹⁹ The takeaway is worth emphasizing: asking your doctor to walk you through what your specific atypia result means in actual numbers, not just vague qualifiers like “slightly increased risk,” can genuinely reduce the anxiety that comes with diagnostic uncertainty.

Part of the stress also comes from the word itself. “Atypia” sounds clinical and ominous, but as one cytopathology commentary noted, the term was originally meant to convey a very low suspicion of cancer, not a high one.¹ Over the decades it has been stretched into broader use, applied in standardized reporting systems for organs that Papanicolaou never intended it for, and loaded with more clinical weight than its original meaning carried. Knowing that history does not change the medical facts of your case, but it can help recalibrate the emotional response. Atypia is a flag for closer attention, not a verdict.

Reactive Versus Neoplastic Atypia

One of the most consequential distinctions in pathology is sorting reactive atypia (cells that look abnormal because of inflammation, infection, or treatment) from neoplastic atypia (cells that are genuinely on a path toward cancer). The two can look strikingly similar under a microscope, and the overlap is a daily source of diagnostic headaches. Reactive changes tend to affect cells uniformly across the tissue, while neoplastic atypia tends to be more localized, with a sharper boundary between normal and abnormal cells. But these rules have exceptions.

In some tissues, persistent inflammation can itself push reactive atypia toward something more dangerous. In the mouth, for example, chronic inflammation produces cells with the same molecular changes seen in true precancerous lesions, including activation of growth-promoting genes and silencing of tumor-suppressor genes.³ The boundary between “reactive” and “precancerous” is not always as clean as textbooks suggest. This is one reason pathologists sometimes hedge their reports with phrases like “favor reactive” or “cannot exclude dysplasia,” language that frustrates patients but honestly reflects genuine uncertainty.

When a Second Opinion Changes the Diagnosis

Given the fair-at-best agreement among pathologists on atypia calls, second opinions carry real weight. The breast pathology study noted earlier, where expert pathologists agreed only modestly on which columnar cell lesions had atypia, is not an outlier.⁸ Similar variability has been documented in thyroid cytology, cervical biopsies, and skin lesions. The practical implication is straightforward: if an atypia diagnosis would lead to surgery, long-term medication, or an intensive surveillance program, having the slides reviewed by a second pathologist (ideally at a center that specializes in that organ) is worth the time and cost. Insurance often covers this, and many pathology departments will proactively request it for borderline cases.

Molecular testing is increasingly filling some of the gaps that visual interpretation leaves open. In thyroid pathology, gene-expression classifiers can help reclassify indeterminate FNA results as likely benign or likely malignant with enough confidence to guide surgical decisions. In cervical screening, HPV genotyping has largely replaced subjective cytology calls for triage. In breast pathology, the tools are less mature, but research into biomarker-based scoring continues. The direction is clear: pathology is gradually moving from purely visual, subjective assessments toward incorporating molecular data that reduce the uncertainty baked into the word “atypia.”